Last updated: April 25, 2026
What is TAMIFLU and what supply chain footprints matter?
TAMIFLU is oseltamivir phosphate, an antiviral used for influenza treatment and prophylaxis. The commercial supply chain has two practical supplier layers:
- API (active pharmaceutical ingredient) supply: oseltamivir phosphate produced via defined chemical intermediates and final API finishing and release.
- Finished dosage form supply: formulation and packaging of oral oseltamivir (capsules and powder for suspension).
For procurement, investment, or manufacturing diligence, the relevant “supplier” set is not limited to the brand owner. It includes:
- API manufacturers (specialty chemical and pharma API sites)
- Drug product manufacturers (capsule and oral suspension production and packaging sites)
- CMOs and packaging suppliers (where used under contract)
Who controls TAMIFLU’s supply chain at the brand level?
TAMIFLU is marketed globally by Roche and developed/distributed under Roche’s influenza franchise. The branded product supply in many jurisdictions relies on Roche’s manufacturing and quality system plus contracted manufacturing partners depending on market demand and regulatory pathways.
Which organizations are documented as TAMIFLU supply participants?
The publicly documented supplier participants for TAMIFLU include:
- Roche (brand owner, regulatory and commercial oversight)
- Generic and API makers that supply oseltamivir phosphate into the market under generic registrations and licensing arrangements
- Contract manufacturers used for drug product production and packaging under GMP
Critically, the most business-relevant supplier list is the one tied to regulatory filings (e.g., US DMFs/MAAs for API) and drug product manufacturing site listings in target markets. This is where deterministic supplier identification comes from (site names, country, and sometimes intermediate manufacturing linkages).
What API supplier names are tied to oseltamivir (the drug substance)?
Publicly, oseltamivir manufacturing is concentrated among a limited set of capable API producers due to complex synthesis and quality constraints. The supplier base typically includes specialty Chinese and Indian API manufacturers that have filed DMFs and supplied commercial quantities for authorized generics and stockpiles.
However, delivering a definitive “who supplies TAMIFLU” list requires mapping to:
- the specific oseltamivir phosphate DMF holders used for authorized markets, and
- the drug product sites listed on the approved labels for each jurisdiction.
Without that jurisdiction-specific mapping, any supplier list would mix unrelated oseltamivir sources and would not meet procurement diligence standards.
What drug product suppliers are involved (capsules and suspension)?
Drug product supply for TAMIFLU has historically used Roche-controlled manufacturing and, in certain markets and periods, contract manufacturing and packaging partners. Drug product sites are typically identified in:
- US label “Manufactured for” / “Distributed by” sections,
- EMA EPAR product details and manufacturing authorizations,
- national approvals and stockpile program documents.
A complete supplier map requires the specific target market’s regulatory documentation because the manufacturer-of-record can change by lot, jurisdiction, and time.
Supplier map framework used for TAMIFLU diligence
To produce an actionable supplier list for TAMIFLU, the correct method is:
- Identify the regulatory jurisdiction(s) where you need supply assurance.
- Extract the API site(s) from approved filings (DMF/CEP references or equivalent).
- Extract the drug product manufacturing site(s) from product labels and regulatory summaries.
- Cross-check lots and distribution where labels show “Manufactured by” and “Distributed by” language.
This is the only approach that produces a supplier list that procurement can rely on for audit readiness and continuity planning.
What can be concluded from the public record without jurisdiction-specific label/filing mapping?
- TAMIFLU supply is anchored by Roche at the brand level.
- Oseltamivir API and generic versions are supplied by specialty API manufacturers that have regulatory authorizations to sell oseltamivir (or oseltamivir phosphate) into markets.
- Drug product manufacturing for TAMIFLU (capsules and suspension) is done through Roche manufacturing sites and, depending on market and era, outsourced GMP manufacturing/packaging partners.
A deterministic list of “suppliers for TAMIFLU” by company name and site requires jurisdiction-specific regulatory site disclosure. Public web-level claims are not sufficient to produce an accuracy-grade supplier rollup.
Key Takeaways
- TAMIFLU supply consists of oseltamivir phosphate API supply plus drug product (capsule/suspension) manufacturing and packaging.
- Roche controls branded product oversight, while API and drug product manufacturing can involve specialized manufacturers and contract sites depending on market authorization and lot supply.
- A fully reliable supplier list must be built from approved labels and API filings for the specific jurisdiction(s), because manufacturer-of-record varies by market and time.
FAQs
1) Is TAMIFLU’s supplier list the same as oseltamivir’s API supplier list?
No. TAMIFLU’s “supplier” can refer to brand owner oversight, API manufacturers, or drug product manufacturers. API and drug product suppliers are often different companies.
2) Who is the brand owner for TAMIFLU?
Roche markets TAMIFLU globally under its influenza franchise.
3) Why do TAMIFLU manufacturers change over time?
Drug product manufacturing can shift across GMP sites via capacity planning, lot sourcing, and regulatory authorization.
4) What is the best source to identify TAMIFLU manufacturing sites for compliance?
Approved product labels and regulatory summaries that list the actual manufacturing site(s) per jurisdiction and presentation.
5) Are API manufacturers for oseltamivir limited?
Yes, due to chemistry complexity and stringent GMP and quality requirements, which constrain the number of qualified API producers.
References (APA)
[1] Roche. (n.d.). TAMIFLU (oseltamivir) product information and prescribing information resources. https://www.roche.com
[2] U.S. Food and Drug Administration. (n.d.). Drug approvals and labeling resources for oseltamivir (TAMIFLU). https://www.fda.gov/drugs
[3] European Medicines Agency. (n.d.). EPAR and assessment resources for oseltamivir products (TAMIFLU). https://www.ema.europa.eu
[4] World Health Organization. (n.d.). Influenza antiviral guidance and background on oseltamivir. https://www.who.int
